- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01961323
Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart
Effects of Nebivolol on Left Ventricular and Left Atrial Morphodynamics in Adults With Hypertension and Isolated Diastolic Dysfunction
Study Overview
Status
Intervention / Treatment
Detailed Description
Background:
The left ventricle (LV) ejects blood with a wringing motion, where the LV apex rotates counterclockwise and the base rotates in clockwise directions respectively. Rapid untwisting and recoil of LV during isovolumic relaxation and early diastole releases energy stored in ejection for LV suction and rapid early diastolic restoration. The LV geometry and its rotational mechanics also give rise to intracavitary blood flow rotation resulting into LV intracavitary vortex ring formation. LV torsion and vortex ring formation confer morphodynamic advantages that gain importance as blood flow velocities, heart rate and rates of change of momentum increase with exertion for improving LV efficiency. We have recently characterized the significance of LV twist mechanics and vortex ring formation in human hearts using novel high resolution speckle and contrast particle tracking echocardiography. Although data on a favorable effect of nebivolol on exercise capacity and LV diastolic filling exists, the changes in left ventricular (LV) rotational mechanics and blood flow vortex ring formation that may explain the potential hemodynamic benefits seen with nebivolol have not been previously characterized.
Aims:
In patients with hypertension and left ventricular diastolic dysfunction (LVDD) treatment with nebivolol for 6 months improves exercise time by enhancing:
- LV deformation, torsion and untwisting mechanics
- LA-to-LV blood flow transport and characteristics of intra-cavitary vortex formation
- LA reservoir and booster pump function and LA-LV interaction during the conduit phase
Hypotheses:
Treatment with nebivolol in subjects with hypertension and LVDD improves exercise time by improving LV deformation and diastolic filling. As diastole shortens with the tachycardia associated with exercise, the contribution of untwist becomes relatively more important to LV suction and filling. Nebivolol improves LV diastolic filling primarily by enhancing LV untwisting and the rheological efficiency of blood flow transport through vortex formation in early diastole.
Significance:
Patients with LVDD are asymptomatic at rest and often but become markedly symptomatic with exertion. This pilot study will provide data for the first time for correlating the improvement in exercise capacity seen with the use of nebivolol with the changes in LV relaxation, torsional mechanics, LV vortex formation and LA-LV transport functions. The preliminary data will be essential for understanding the underlying pathophysiological mechanisms through which nebivolol improves exercise hemodynamics besides providing data for development of subsequent larger randomized multicentric trials.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- History of mild (140-160 / 90-100) to moderate (160-200 / 100-120) hypertension
- LV diastolic dysfunction (>/= Grade1)
- LV ejection fraction >50%
- Indexed left atrial volume >/= 28 mL/m^2
- In sinus rhythm at the time of enrollment
- Willingness to return for the 6-month follow up investigations
Exclusion Criteria:
Presence or history of any of the following at baseline:
- History of mitral valve disease of greater than mild severity or prosthetic mitral valve, congenital heart disease or permanent pacemaker
- Calculated creatinine clearance <50 mL/min
- Terminal Illness with expected Survival of <1 year
- Previous Heart Transplant
- Individuals who are institutionalized
- Systolic BP>180 mm Hg or diastolic BP > 120 mm Hg
Medical treatment for elevated BP with:
- Calcium channel blocker (e.g. verapamil, nifedipine);
- Alpha blocker (e.g. prazosin);
- Alpha agonist (e.g. α-methyldopa, hydralazine, clonidine)
- Patient unwilling or unable to provide informed consent for study participation
- Pregnancy (current, or anticipated within the study period)
- Secondary Hypertension
- Previous echo contrast allergy
- Poor echocardiography window
- Previous stroke, known carotid stenosis
- Contraindication for beta-blocker therapy (sinus bradycardia <50 beats/min);
- 2nd or 3rd degree AV conduction block
- Overt congestive cardiac failure (NYHA Class III-IV)
- Known bronchospastic disease
- Known hepatic dysfunction (SGOT/PT > twice above normal levels)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Nebivolol
Nebivolol 5 mg (titrated to a maximal dose of 10mg for optimal blood pressure) for 6 months
|
Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP<140 and DBP <90 mm Hg.
If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day.
If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in Exercise Tolerance
Time Frame: at 6 months
|
measured by stress echocardiogram, number of participants who had improvement in METS and improvement in exercise time as compared to their baseline.
|
at 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
E Velocity Indexed to e' (E/e' Ratio) of the Left Ventricle
Time Frame: at 6 months
|
measured as a part of stress echocardiogram, E/e' ratio: The normal E/e' ratio from the medial annulus is <8 and suggests a normal left atrial pressure.
While values between 8 and 12 are indeterminate, a value >12 is indicative of an elevated left atrial pressure or PCWP (>18mmHg).
The ranges for E/e' from the lateral mitral annulus are <5, 5 -10 and >10 respectively.
|
at 6 months
|
Untwist Rate of the Left Ventricle
Time Frame: at 6 months
|
measured as a part of stress echocardiogram, number of participants with significant improvement in the LV untwist after Nebivolol treatment in patients who completed the study
|
at 6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Partho Sengupta, MD, Icahn School of Medicine at Mount Sinai
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Ventricular Dysfunction
- Hypertension
- Ventricular Dysfunction, Left
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Adrenergic Agonists
- Adrenergic beta-Agonists
- Adrenergic beta-1 Receptor Agonists
- Nebivolol
Other Study ID Numbers
- GCO 12-0493
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
Clinical Trials on Nebivolol
-
Forest LaboratoriesCompletedStage 2 Hypertension | Stage 1 HypertensionUnited States
-
Bio-innova Co., LtdNot yet recruitingHealthy Subjects
-
University of AbujaMicronova Pharmaceuticals Ind LtdCompleted
-
East Coast Institute for ResearchCompletedHypertension | Female Sexual DysfunctionUnited States
-
Ain Shams UniversityRecruiting
-
Forest LaboratoriesCompletedStage 2 Diastolic HypertensionUnited States, Puerto Rico
-
Jack RubinsteinForest LaboratoriesTerminated
-
Forest LaboratoriesCompletedHypertensionUnited States
-
Menarini International Operations Luxembourg SACompleted
-
Betaliq, Inc.Trial Runners, LLC; Summit Analytical, LLCCompletedOcular Hypertension | Open-Angle GlaucomaUnited States